This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
If you want steady income from a single stock, think about an integrated energy company that currently yields about 4...
President Trump dismissed the 21st Century ROAD to Housing Act as a yawn and canceled a signing ceremony, redirecting...
Governor Newsom signs a balanced budget, delivering a zero-deficit forecast for two years while locking in $1.7 billi...
Marvell Technology extended a dramatic rally, up 45% in a month on record revenue, while investors weigh whether to t...
Investors confront a tough choice: buy Nvidia for big gains or rely on NVDY's weekly income stream, which comes with ...
Carlisle Companies is pursuing Owens Corning with an unsolicited offer, aiming to transform into a larger, more diver...
AI-generated listing videos are reshaping real estate marketing, but new disclosures aim to curb misrepresentation. T...
A government-backed AI initiative is building a data backbone to test nutrition-focused ideas in farming. Early pilot...
A new survey finds a notable share of senior executives view data collection and use as ethically troubling, foreshad...
Microsoft and Twitter are introducing AI-focused bug bounty programs to surface safety flaws and bias. The move refle...
Business and academia are joining forces to accelerate practical AI, with new joint labs, funding, and internships sh...